Growth

MGF (Mechano Growth Factor)

Peptide · IGF-1 splice variant · 24 amino acids

FDA · CATEGORY 2 (2023)

Half-life

~6 minutes

Very short

minsdays

Route

IM injection

Evidence

Preclinical only

Risk

Standard

Overview

Known for

Splice variant of IGF-1 released locally by damaged muscle tissue. Promotes muscle satellite cell activation and repair. Very short half-life (~5-7 minutes).

Mechanism

Splice variant of IGF-1 produced by damaged muscle tissue. Proposed to activate satellite cells for localised muscle repair.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
Natural / Topping UpNatural
FDA category
Category 2 (2023)

Evidence & standing

Evidence base
Preclinical only
Risk level
Standard

Dosage & protocol

Typical dose
100-200mcg
Research range
100–200 µg
Cycle
4 weeks on / 4 weeks off
Half-life
~5-7min
~5-7 minutes (extremely short — limits utility)
Protocol

100-200mcg IM bilaterally into trained muscle, immediately post-workout. Due to short half-life, timing is critical.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Injection site pain, limited safety data

Interactions

Unknown — very limited research

Do not combine
PEG-MGFPEG-MGF

Handle with research caution

Common Side Effects Injection site pain, limited safety data Drug Interactions Unknown — very limited research Reversibility Fully reversible — extremely short acting

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
2–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.